EPILEPSY is one of the most common neurologic disorders; it affects
about 1% of the population in the United States and Canada.1
Despite treatment with traditional antiepileptic drugs (AEDs), more than 30%
of patients with epilepsy either have inadequate seizure control or experience
significant adverse drug effects. In the past 4 years, new options for the
medical treatment of epilepsy have been introduced, including novel AEDs,
improved formulations of older AEDs, and the vagus nerve stimulator (VNS).
The new AEDs differ from older agents in several important ways, including
mechanism of action, spectrum of activity, pharmacokinetics, and adverse effect
profiles (Table 1).
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.